Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-2.16% $3.63
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 44.93 mill |
EPS: | -0.840 |
P/E: | -4.32 |
Earnings Date: | Apr 12, 2024 |
SharesOutstanding: | 12.38 mill |
Avg Daily Volume: | 0.480 mill |
RATING 2024-03-28 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.32 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.73x |
Company: PE -4.32 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-1.563 (-143.06%) $-5.19 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 3.09 - 4.19 ( +/- 15.00%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Cabatuan Nelson | Sell | 200 000 | Stock Options |
2023-10-26 | Carle Vanessa | Buy | 12 500 | Stock Options |
2023-10-26 | Docherty John Martin | Buy | 30 000 | Stock Options |
2023-10-26 | Bunka Christopher | Buy | 30 000 | Stock Options |
2023-07-25 | Baxter Nicholas W | Buy | 5 000 | Stock Options |
INSIDER POWER |
---|
-22.08 |
Last 99 transactions |
Buy: 4 974 810 | Sell: 2 651 735 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.63 (-2.16% ) |
Volume | 0.168 mill |
Avg. Vol. | 0.480 mill |
% of Avg. Vol | 35.04 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.